Advances in the study of inhibitors of kinases and nuclear factors for treating allergic asthma

Yaoxue Xuebao

Volumn 47, Issue 6, 2012, Pages 689-695

  Liu, Ren Ping ^a,b   Meng, Ai Min ^b   Hou, Qi ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Airway hyperresponsiveness; Asthma; Nuclear transcription factor; Serine threonine kinase; Tyrosine kinase

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NUCLEAR FACTOR; NUCLEAR FACTOR INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PROTEIN FUNCTION; RESPIRATORY TRACT ALLERGY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ASTHMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84865339547     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Holgate ST, Polosa R. Treatment strategies for allergy and asthma [J]. Nature, 2008, 8: 218-230.
2. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma [J]. Lancet, 2008, 372: 1073-1087.
3. Lenferink AE, Simpson JF, Shawver LK, et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+ MMTV/TGF-α bigenic mice [J]. Proc Natl Acad Sci USA, 2000, 97: 9609-9614.
4. Cortijo J, Mata M, Milara J, et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways [J]. Eur Respir J, 2011, 37: 244-254.
5. Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance [J]. Immunol Rev, 2009, 228: 9-22.
6. Sahu N, August A. ITK inhibitors in inflammation and immune-mediated disorders [J]. Curr Top Med Chem, 2009, 9: 690-703.
7. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors [J]. Expert Opin Ther Pat, 2009, 19: 1361-1376.
8. Matsubara S, Li G, Takeda K, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness [J]. Am J Respir Crit Care Med, 2006, 173: 56-63.
9. Saini SS, Paterniti M, Vasagar K. Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2 [J]. Clin Immunol, 2009, 132: 342-348.
10. Malaviya R, Chen CL, Navara C, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-dibromo-4′-hydroxyphenyl) amino-6, 7-dimethoxyquinazoline (WHI-P97) [J]. J Pharmacol Exp Ther, 2000, 295: 912-926.
11. Malaviya R, Zhu D, Dibirdik I, et al. Targeting janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis [J]. J Biol Chem, 1999, 274: 27028-27038.
12. Löber K, Alfonso A, Escribano L, et al. Influence of the tyrosine kinase inhibitors STI571 (Glivec®), lavendustin A and genistein on human mast cell line (HMC-1560) activation [J]. J Cell Biochem, 2008, 103: 1076-1088.
13. Shih CH, Lin LH, Lai YH, et al. Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects [J]. Eur J Pharmacol, 2010, 643: 113-120.
14. Heo HJ, Lee SY, Lee MN, et al. Genistein and curcumin suppress epidermal growth factor-induced MUC5AC mucin production and gene expression from human airway epithelial cells [J]. Phytother Res, 2009, 23: 1458-1461.
15. Tedeschi A, Lorini M, Galbiati S, et al. Inhibition of basophil histamine release by tyrosine kinase and phosphatidylinositol 3-kinase inhibitors [J]. Int J Immunopharmacol, 2000, 22: 797-808.
16. Tsang F, Choo HH, Dawe GA, et al. Inhibitors of the tyrosine kinase signaling cascade attenuated thrombin-induced guinea pig airway smooth muscle cell proliferation [J]. Biochem Biophys Res Commun, 2002, 293: 72-78.
17. Haeryfar SMM, Hoskin DW. Selective pharmacological inhibitors reveal differences between Thy-1- and T cell receptor-mediated signal transduction in mouse T lymphocytes [J]. Int Immunopharmacol, 2001, 1: 689-698.
18. Harada Y, Watanabe S, Yssel H, et al. Factors affecting the cytokine production of human T cells stimulated by different modes of activation [J]. J Allergy Clin Immunol, 1996, 98: 161-173.
19. Erpenbeck VJ, Fischera I, Wiese K, et al. Therapeutic surfactants modulate the viability of eosinophils and induce inflammatory mediator release [J]. Int Arch Allergy Immunol, 2009, 149: 333-342.
20. Duan W, Aguinaldo D, Leung BP, et al. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model [J]. Int Immunopharmacol, 2005, 5: 495-502.
21. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-δ with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2010, 182: 897-904.
22. Sharma P, Halayko AJ. Emerging molecular targets for the treatment of asthma [J]. Indian J Biochem Biophys, 2009, 46: 447-460.
23. Munoz L, Ramsay EE, Manetsch M, et al. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle [J]. Eur J Pharmacol, 2010, 635: 212-218.
24. Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma [J]. Eur Respir J, 2010, 35: 4750-4756.
25. Barnes PJ. Role of GATA-3 in allergic diseases [J]. Curr Mol Med, 2008, 8: 330-334.
26. Eynott PR, Xu L, Bennett BL, et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats [J]. Immunology, 2004, 112: 446-453.
27. Burgess JK, Heelee J, Ge Q, et al. Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma [J]. J Cell Physiol, 2008, 216: 673-679.
28. Duan W, Chan JH, Wong CH, et al. Anti-inflammatory effects of mitogen-activated protein kinase inhibitor U0126 in an asthma mouse model [J]. J Immunol, 2004, 172: 7053-7059.
29. Caruso R, Stolfi C, Sarra M, et al. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 MAP kinase-dependent induction of Socs-3 [J]. Blood, 2009, 113: 3512-3519.
30. Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence [J]. J Pharmacol Exp Ther, 2000, 293: 281-288.
31. Desmet C, Gosset P, Pajak B, et al. Selective blockade of NF-κB activity in airway immune cells inhibits the effector phase of experimental asthma [J]. J Immunol, 2004, 173: 5766-5775.
32. Huang TJ, Adcock IM, Chung KF. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat [J]. Br J Pharmacol, 2001, 134: 1029-1036.
33. Henderson WR, Chi EC, Teo JL, et al. A small molecule inhibitor of redox-regulated NF-kappaB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model [J]. J Immunol, 2002, 169: 5294-5299.
34. Folmer F, Jaspars M, Dicato M, et al. Marine natural products as targeted modulators of the transcription factor NF-κB [J]. Biochem Pharmacol, 2008, 75: 603-617.
35. Xu WP, Li WD. SOCS3: a potential therapeutic target for many human disease [J]. Acta Pharm Sin, 2011, 46: 747-752.
36. Quarcoo D, Weixler S, Groneberg D, et al. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity [J]. J Allergy Clin Immunol, 2004, 114: 288-295.
37. Chiba Y, Todoroki M, Nishida Y, et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice [J]. Am J Respir Cell Mol Biol, 2009, 41: 516-524.
38. Kubo M, Inoue H. Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia [J]. Curr Allergy Asthma Rep, 2006, 6: 32-39.